Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SGT 501

Next Previous
Drug Profile

SGT 501

Alternative Names: SGT-501

Latest Information Update: 21 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Solid Biosciences
  • Class Antiarrhythmics; Gene therapies
  • Mechanism of Action CASQ2 protein replacements; Gene transference; Ryanodine receptor calcium release channel replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polymorphic catecholergic ventricular tachycardia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Polymorphic catecholergic ventricular tachycardia

Most Recent Events

  • 23 Feb 2026 Phase-I clinical trials in Polymorphic catecholergic ventricular tachycardia (In children, In adolescents, In adults, In the elderly) in USA and Canada (IV) (NCT07148089)
  • 08 Sep 2025 Solid Biosciences plans the first-in-human phase Ib ARTEMIS trial for Polymorphic catecholergic ventricular tachycardia (In children, In adolescents, In adults, In the elderly) in USA (IV, Infusion), in October 2025 (NCT07148089),
  • 23 Jul 2025 SGT 501 receives Fast Track designation for Polymorphic catecholergic ventricular tachycardia [Parenteral] in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top